Blood Group and COVID-19 Transmission and Mortality in Patients With Malignant Disease

  • Senar Ebinç* Department of Medical Oncology, Dicle university, Diyarbakır, Turkey
  • Zeynep Oruç Department of Medical Oncology, Dicle university, Diyarbakır, Turkey
  • Ziya Kalkan Department of Medical Oncology, Dicle university, Diyarbakır, Turkey
  • Zuhat Urakçı Department of Medical Oncology, Dicle university, Diyarbakır, Turkey
  • Muhammet Ali Kaplan Department of Medical Oncology, Dicle university, Diyarbakır, Turkey
  • Mehmet Küçüköner Department of Medical Oncology, Dicle university, Diyarbakır, Turkey
  • Abdurrahman Işıkdoğan Department of Medical Oncology, Dicle university, Diyarbakır, Turkey

Abstract

Aim: The study aimed to investigate risk factors affecting the transmission of and mortality from COVID-19 in patients diagnosed with a malignant disease. In this context, ABO blood groups, gender, age, type of malignant disease, type of anti-tumoral agents, comorbidities and stage were examined.


Materials and Methods: Files of 1,256 patients who presented to our clinic between March and December 2020 were retrospectively reviewed. Patients diagnosed with a malignant disease who became infected with COVID-19 and those who did not were compared with regard to demographic, clinical characteristics and laboratory results (status of having been infected with COVID-19, ABO blood groups).


Results: Of 1256 patients in total, 72 (5.7%) were diagnosed with COVID-19. Median age of cancer patients infected with COVID-19 was 53 years (18-80). The most common types of cancer included gastrointestinal cancer (22.2%), breast cancer (20.8%), genitourinary cancer (20.8%) and lung cancer (16.7%). Of the patients diagnosed with COVID-19, 18.1% (n=13) died. Multivariate analysis identified disease stage as an independent prognostic factor for the risk of mortality [HR: 0.07, 95% CI (0.007-0.74), (p=0.02)]. A comparison of patients who became infected with COVID-19 and those who did not with regard to ABO blood groups (p=0.39) showed no statistically significant differences between the two groups. There was also no correlation between ABO blood groups and the risk of COVID-19-related mortality (p=0.83).


Conclusion:  In patients suffering from malignant diseases, the ABO blood type exhibited no correlation with the risk of COVID-19 transmission and mortality. This study determined the presence of metastatic disease as a negative prognostic factor. Patients suffering from a metastatic malignant disease represent a high risk group for COVID-19 and should be treated using all necessary precautions.

Published
Nov 26, 2021
How to Cite
EBINÇ*, Senar et al. Blood Group and COVID-19 Transmission and Mortality in Patients With Malignant Disease. Southeastern European Medical Journal, [S.l.], v. 5, n. 2, p. 1-8, nov. 2021. ISSN 2459-9484. Available at: <http://seemedj.mefos.unios.hr/index.php/seemedj/article/view/205>. Date accessed: 28 jan. 2022. doi: http://dx.doi.org/10.26332/seemedj.v5i2.205.
Section
Articles